UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-QSB
QUARTERLY REPORT PURSUANT TO SECTIOIN 13 OR 15 (d)
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE PERIOD ENDED: January 31, 2005
COMMISSION FILE NUMBER: 000-31727
THE QUANTUM GROUP, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
NEVADA 20-0774748
-------------------------------- --------------------
State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)
3460 Fairlane Farms Road, Suite 4, Wellington, Florida 33414
-------------------------------------------------------------
(Address, including zip code, of principal executive offices)
(561) 798-9800
--------------------------------------------------
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all documents and
reports required to be filed by Sections 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filings for the past 90 days. YES [X] NO [ ]
APPLICABLE ONLY TO CORPORATE ISSUERS:
As of March 7, 2005 the number of the Company's shares of par value $.001
common stock outstanding was 19,325,829.
INDEX
Part I - FINANCIAL INFORMATION
Item 1 - Financial Statements-Unaudited
Condensed Balance Sheet 3
Condensed Statements of Operations 4
Condensed Statement of Changes in Deficiency in Assets 5
Condensed Statements of Cash Flows 6
Notes to Condensed Financial Statements 7
Item 2- Management's Discussion and Analysis of Financial Condition
And Results of Operations 11
Item 3- Controls and Procedures 13
PART II - OTHER INFORMATION 13
SIGNATURES 14
2
PART I
ITEM 1. FINANCIAL INFORMATION.
The Quantum Group, Inc.
Balance Sheet
(A Development Stage Enterprise)
January 31, 2005
(unaudited)
ASSETS
Current assets:
Cash $ 29,143
-----------
Total current assets 29,143
Property and equipment, net of accumulated depreciation of $10,547 131,908
Goodwill 23,500
Other assets 42,265
-----------
Total assets $ 226,816
===========
LIABILITIES AND SHAREHOLDERS' DEFICIT
Current liabilities:
Accounts payable and accrued liabilities $ 372,412
Accrued payroll 596,109
Notes payable and accrued interest - shareholder 238,174
-----------
Total current liabilities 1,206,695
Capital Lease Obligation 6,029
-----------
Total Liabilities 1,212,724
Commitments and contingencies
Deficiency in assets accumulated during development stage (985,908)
-----------
Total liabilities and deficiency in assets $ 226,816
===========
See accompanying notes to condensed financial statements
3
The Quantum Group, Inc.
Statement of Operations
( A Development Stage Enterprise)
For the Periods Ended January 31, 2005 and 2004
(unaudited)
For the period
For the period ended July 24, 2001
------------------------------------- (inception) to
January 31, 2005 January 31, 2004 January 31, 2005
---------------- ---------------- ----------------
Interest Expense $ 9,685 $ 9,356 $ 80,674
Other Expenses 412,219 146,178 1,921,747
------------ ----------- ----------
Expenses Representing Net Loss $ 421,904 $ 155,534 $2,002,421
============ =========== ==========
Basic and diluted (loss) per common share $ (0.02) $ (0.05)
=========== =========
Weighted average number of common shares
outstanding 18,605,995 3,320,889
============ =========
See accompanying notes to condensed financial statements
4
The Quantum Group, Inc.
Statement of Changes in Deficiency in Assets Accumulated
During the Development Stage
October 31, 2004
Preferred Stock Common Stock
par value $.001 par value $.001
per share per share
30,000,000 authorized 170,000,000 authorized Addition
--------------------- ------------------------ Paid-in Deferred
# of shares Amount # of Shares Amount Capital Compensation
---------- ------ ---------- ------- ----------- ------------
Balance at 10-31-01 -- -- 2,700,000 2,700 17,300 --
Net (loss) -- -- -- -- -- --
------- ---- ---------- ------- ----------- ---------
Balance at 10/31/02 -- -- 2,700,000 2,700 17,300 --
Merger with TPII -- -- 510,885 511 (121,363) --
Sale of common stock for cash -- -- 86,000 86 64,914 --
Deferred compensation-stock options -- -- -- -- 207,500 (207,500)
Deferred compensation-stock grants -- -- -- -- -- (327,150)
Amortization of deferred comp -- -- -- -- -- 3,458
Net (loss) -- -- -- -- -- --
------- ---- ---------- ------- ----------- ---------
Balance at 10/31/03 -- -- 3,296,885 3,297 168,351 (531,192)
Sale of common stock -- -- 1,188,122 1,188 276,690 --
Conversion of note payable -- -- 300,000 300 164,700 --
Issuance of stock - stk grants -- -- 197,269 197 172,551 172,748
Amortization of deferred compensation -- -- -- -- -- 83,975
Stock based compensation -- -- 25,000 25 23,475 --
Merger - Renaissance Health Systems, Inc. 100,000 100 9,300,000 9,300 -- --
Merger - Quantum Medical Technologies, Inc. 100,000 100 4,000,000 4,000 -- --
Deferred compensation-stock grants -- -- -- -- -- (45,950)
Grant of stock options -- -- -- -- 79,800 (79,800)
Net (loss) -- -- -- -- -- --
------- ---- ---------- ------- ----------- ---------
Balance at 10/31/04 200,000 $200 18,307,276 $18,307 $ 885,567 $(400,219)
======= ==== ========== ======= =========== =========
Sale of common stock -- -- 917,778 917 226,934 --
Issuance of stock - stk grants -- -- 36,775 37 31,197 31,234
Stock based compensation -- -- 6,500 6 3,049 --
Stock issued in lieu of cash -- -- 57,500 58 29,268 --
Amortization of deferred compensation -- -- -- -- -- 20,840
Deferred compensation-stock grants -- -- -- -- -- (26,512)
Deferred compensation-stock options -- -- -- -- 68,250 (68,250)
Net (loss) -- -- -- -- -- --
------- ---- ---------- ------- ----------- ---------
Balance at 1/31/05 200,000 $200 19,325,829 $19,325 $ 1,244,265 $(442,907)
======= ==== ========== ======= =========== =========
[RESTUBBED]
Allocated
Shares
for Deferred Accumulated Total
Compensation Deficit Equity
--------- ----------- -----------
Balance at 10-31-01 -- (127,576) (107,576)
Net (loss) -- (86,400) (86,400)
--------- ----------- -----------
Balance at 10/31/02 -- (213,976) (193,976)
Merger with TPII -- -- (120,852)
Sale of common stock for cash -- -- 65,000
Deferred compensation-stock options -- -- --
Deferred compensation-stock grants $ 327,150 -- --
Amortization of deferred comp -- -- 3,458
Net (loss) -- (246,555) (246,555)
--------- ----------- -----------
Balance at 10/31/03 327,150 (460,531) (429,925)
Sale of common stock -- -- 277,878
Conversion of note payable -- -- 165,000
Issuance of stock - stk grants (172,748) -- 172,748
Amortization of deferred compensation -- -- 83,975
Stock based compensation -- -- 23,500
Merger - Renaissance Health Systems, Inc. -- -- 9,400
Merger - Quantum Medical Technologies, Inc. -- -- 4,100
Deferred compensation-stock grants 45,950 -- --
Grant of stock options -- -- --
Net (loss) -- $(1,119,986) (1,119,986)
--------- ----------- -----------
Balance at 10/31/04 $ 200,352 $(1,580,517) $ (876,310)
========= =========== ===========
Sale of common stock -- -- 227,851
Issuance of stock - stk grants (31,234) -- 31,234
Stock based compensation -- -- 3,055
Stock issued in lieu of cash -- -- 29,326
Amortization of deferred compensation -- -- 20,840
Deferred compensation-stock grants 26,512 -- --
Deferred compensation-stock options -- -- --
Net (loss) -- (421,904) (421,904)
--------- ----------- -----------
Balance at 1/31/05 $ 195,630 $(2,002,421) $ (985,908)
========= =========== ===========
See accompanying notes to condensed financial statements
5
The Quantum Group, Inc.
(A Development Stage Enterprise)
Statements of Cash Flow
For the Periods Ended January 31, 2005 and 2004
Three Months Three Months July 24, 2001
ended ended (Inception) to
January 31, 2005 January 31, 2004 January 31, 2005
---------------- ---------------- ----------------
OPERATING ACTIVITIES
Net (loss) $(421,904) $(155,534) (2,002,421)
--------- --------- -----------
Adjustments to reconcile net loss to net cash used in
operating activities:
Depreciation 3,588 330 10,547
Amortization of deferred compensation 20,840 74,502 108,273
Issuance of stock for compensation 63,613 -- 259,861
Loss on conversion of debt to common stock -- -- 135,000
Changes in operating assets and liabilities:
Increase in other assets (29,014) (97) (42,264)
Increase in accounts payable and accrued liabilities 232,642 68,177 882,102
--------- --------- -----------
Total adjustments 291,669 142,912 1,353,519
--------- --------- -----------
Net cash used in operating activities (130,235) (12,622) (648,902)
INVESTING ACTIVITIES
Purchase of property and equipment (83,040) (214) (131,918)
Investment in related companies -- -- (10,000)
--------- --------- -----------
Net cash used in investing activities (83,040) (214) (141,918)
--------- --------- -----------
FINANCING ACTIVITIES
Proceeds (repayments) on notes payable (20,647) 14,300 230,480
Proceeds from issuance of common stock 227,853 -- 590,731
Repayments on capital lease obligation (756) -- (1,248)
--------- --------- -----------
Net cash provided by financing activities 206,450 14,300 819,963
--------- --------- -----------
Net increase (decrease) in cash (6,825) 1,464 29,143
Cash at beginning of period 35,968 242 --
--------- --------- -----------
Cash at end of period $ 29,143 $ 1,706 $ 29,143
========= ========= ===========
Supplemental disclosures of cash flow information:
Cash paid during the period for interest $ 5,071 $ -- $ 7,279
Supplemental disclosures of non-cash investing and
financing activities:
Assumption of Liabilities of Transform Pack International, Inc. $ -- $ -- $ 120,852
Common stock and preferred stock issued in connection
with acquisitions $ -- $ -- $ 23,500
Capital lease obligations incurred on purchases of equipment $ -- $ -- $ 10,358
Conversion of convertible note into common stock $ -- $ -- $ 30,000
See accompanying notes to condensed financial statements.
6
THE QUANTUM GROUP, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO CONDENSED FINANCIAL STATEMENTS - (UNAUDITED)
JANUARY 31, 2005
NOTE 1: DESCRIPTION OF COMPANY
On May 28, 2003, Transform Pack International, Inc. (the "Company") merged with
Quantum HIPAA Consulting, Inc ("Quantum"). On January 30, 2004, the shareholders
of the Company approved the reincorporation of the Company under the name of The
Quantum Group, Inc. ("TQGI"). The shareholders approved a 1 for 10 reverse stock
split. The Company is a development stage company with no current revenues. The
Company's business model is to become a provider of services to the healthcare
industry in three complementary areas: outsourcing administrative
responsibilities for physicians, Managed Care Organizations, healthcare
facilities and physician associations; developing new technologies for the
healthcare delivery system; and providing healthcare services to consumers.
Basis of Presentation
The condensed financial statements of The Quantum Group, Inc. (the "Company")
have been prepared in accordance with generally accepted accounting principles
for interim financial information and Regulation S-B. Accordingly, they do not
include all of the information and notes required by generally accepted
accounting principles for complete financial statements.
The accompanying condensed financial statements of the Company are unaudited.
However, in the opinion of management, they include all adjustments necessary
for a fair presentation of financial position, results of operations and cash
flows. All adjustments made during the three months ended January 31, 2005, were
of a normal, recurring nature. The amounts presented for the three months ended
January 31, 2005, are not necessarily indicative of the results to be expected
for any other interim period or for the entire fiscal year. Additional
information is contained in the Annual Report on Form 10-KSB of the Company for
the year ended October 31, 2004, which should be read in conjunction with this
quarterly report.
Going Concern
The Company has no revenues to date. Since its inception, the Company has been
dependent upon the receipt of capital investment to fund its continuing
activities. In addition to the normal risks associated with a new business
venture, there can be no assurance that the Company's business plan will be
successfully executed. The Company's ability to execute its business model will
depend on its ability to obtain additional financing and achieve a profitable
level of operations. There can be no assurance that sufficient financing will be
obtained. Nor can any assurance be made that the Company will generate
substantial revenues or that the business operations will prove to be
profitable. These conditions raise substantial doubt about the Company's ability
to continue as a going concern. The financial statements do not include any
adjustments that might result from the outcome of these uncertainties.
NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Cash Equivalents
The Company considers all highly liquid debt instruments with original
maturities of three months or less to be cash equivalents. At January 31, 2005
there were no cash equivalents.
7
THE QUANTUM GROUP, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO CONDENSED FINANCIAL STATEMENTS - (UNAUDITED)
JANUARY 31, 2005
NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Property and Equipment
Furniture and equipment are stated at cost. Depreciation is calculated using the
straight-line method over the estimated useful lives of the assets, which range
from three to five years.
Research and Development Costs
Research and development costs are charged to expense when incurred.
Use of Estimates
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amount of revenues and expenses during the reporting period. Actual
results could differ from those estimates and the differences could be material.
Income Taxes
The Company has not recognized any benefit of such net operating loss carry
forwards in the accompanying financial statements in accordance with the
provisions of SFAS No. 109, as the realization of this deferred tax benefit is
not likely. A 100% valuation allowance has been recognized to offset the entire
effect of the Company's net deferred tax asset.
Goodwill
On an annual basis, management assesses the composition of the Company's assets
and liabilities, as well as the events that have occurred and the circumstances
that have changed since the most recent fair value determination. If events
occur or circumstances change that would more likely than not reduce the fair
value of goodwill below its carrying amount, goodwill will be tested for
impairment. The Company will recognize an impairment loss if the carrying value
of the asset exceeds the fair value determination. As of January 31, 2005, there
was no impairment of goodwill.
Principles of Consolidation
The accompanying consolidated financial statements for the period ended January
31, 2005 include the accounts of The Quantum Group, Inc. and its subsidiaries,
Renaissance Health Systems, Inc. and Quantum Medical Technologies, Inc.
Revenue Recognition
It is anticipated that the Company will recognize a majority of its revenue from
Health Maintenance Organizations (HMO) as a percentage of premium collected by
the HMO from governmental sources. These payments are paid at the beginning of
each month, with quarterly adjustments as required on a look back basis to
account for any disenrollments. Revenue will be recorded in the month earned
with an allowance for the quarterly adjustments.
8
THE QUANTUM GROUP, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO CONDENSED FINANCIAL STATEMENTS - (UNAUDITED)
JANUARY 31, 2005
NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Stock Compensation
The company has adopted Statement of Financial Accounting Standards No. 123
("SFAS 123"), "Accounting for Stock-Based Compensation." SFAS 123 encourages the
use of a fair-value-based method of accounting for stock-based awards, under
which the fair value of stock options is determined on the date of grant and
expensed over the vesting period. Under SFAS 123, companies may, however,
measure compensation costs for those plans using the method prescribed by
Accounting Principles Board Opinion No. 25 ("APB No. 25"), "Accounting for Stock
Issued to Employees." Companies that apply APB No. 25 are required to include
pro forma disclosures of net earnings and earnings per share as If the
fair-value-based method of accounting had been applied. The Company elected to
account for such plans under the provisions of APB No. 25. The Company accounts
for stock options granted to consultants under SFAS 123.
Had the compensation expense for the stock option plan been determined based on
the fair value of the options at the grant date consistent with the methodology
prescribed under Statement of Financial Standards No. 123, "Accounting for Stock
Based Compensation," at January 31, the Company's net income and earnings per
share would have been reduced to the pro forma amounts indicated below:
2005 2004
--------------- ----------------
Net income (loss)
as reported $ (421,904) $ (155,534)
----------- -----------
pro forma $ (462,294) $ (163,834)
----------- -----------
Earnings per share
As reported $ (0.02) $ (0.05)
----------- -----------
Pro forma $ (0.02) $ (0.05)
----------- -----------
The fair value of each option is estimated on the date of grant using the fair
market value option-pricing model with the assumptions:
Risk-free interest rate 3%
Expected life (years) 5
Expected volatility 1.39
Expected dividends None
New Accounting Pronouncements
In December 2004, the FASB issued SFAS No. 153 "Exchanges of Non-monetary
Assets-an amendment of APB Opinion No. 29". This Statement amended APB Opinion
No. 29 to eliminate the exception for non-monetary exchanges of similar
productive assets and replaces it with a general exception for exchanges of
non-monetary assets that do not have commercial substance. A non-monetary
exchange has commercial substance if the future cash flows of the entity are
expected to change significantly as a result of the exchange. The Company is
currently evaluating the impact of this new standard, but believes that it will
not have a material impact upon the Company's financial position, results of
operations or cash flows.
9
THE QUANTUM GROUP, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO CONDENSED FINANCIAL STATEMENTS - (UNAUDITED)
JANUARY 31, 2005
NOTE 3: FAIR VALUE OF FINANCIAL INSTRUMENTS
The carrying amounts of cash and cash equivalents, accounts payable, notes
payable and accrued liabilities approximate their fair value because of the
short maturity of these financial instruments.
NOTE 4: MERGER WITH QUANTUM HIPAA CONSULTING, INC.
Effective May 28, 2003, the Company consummated a merger pursuant to a merger
agreement with Quantum HIPAA Consulting Group, Inc. Quantum HIPAA Consulting
Group, Inc. developed a training compact disc and manuals to instruct the
healthcare industry on the implementation of the regulations created to comply
with the Health Insurance Portability and Accountability Act of 1996 (HIPAA).
The Company completed the merger by issuing 2,700,000 million shares of Common
Stock to the sole shareholder of Quantum, in exchange for all the issued and
outstanding shares of Quantum. For accounting purposes, the acquisition was
treated as a recapitalization of the Company. The value of the net assets of the
Company after the acquisition was completed is the same as their historic book
value.
On May 30 2003, in accordance with the agreement, the Company, Transform Pack
International, Inc., sold its wholly owned subsidiary, Transform Pack, Inc.
(TPI) to certain previous shareholders and investors of the Company. Transform
Pack, Inc. and its shareholders have agreed to assume and indemnify the Company
for all operating debts of the Company.
NOTE 5: ACQUISITION OF QUANTUM MEDICAL TECHNOLOGIES, INC. AND RENAISSANCE HEALTH
SYSTEMS, INC.
Following a motion approved by the Company's shareholders during a meeting
January 30, 2004, the Board of Directors agreed to issue 13,300,000 post reverse
shares and 200,000 shares of Series A preferred stock, approved separately by
the Board of Directors on July 19, 2004, to the shareholder of both Quantum
Medical Technologies, Inc. (QMT) and Renaissance Health Systems, Inc. (RHS) for
the 80% of the those companies which the Company does already not own from the
majority shareholder of the Company. The Series A preferred stock is convertible
into 30 common shares after 4 years at the option of the holder. Control in the
Company will not materially change, since all the shareholders in numbers and
relative beneficial ownership of both QMT and RHS are also material and
beneficial owners of the common shares of the Company today. The final merger
was consummated in August 2004.
Quantum Medical Technologies, Inc. (QMT) was incorporated in January of 2000,
and is a developmental stage company, with no significant material assets or
liabilities and no revenues, and consists primarily of intellectual and patent
pending business process to provide medical technologies, computer programs,
electronic services, predictive modeling and other services to the medical
profession. The Company has begun to develop a Cybernaptic (SM) process to
connect in an applications service provider (ASP) format most of the touch
points in the healthcare delivery system. The Company has also in development a
QuantumQuotient (SM) index that the Company believes could be used as a tool to
provide a measurable way to tack improvement in the healthcare lifestyle of its
subject. If this process can be confirmed, it could have significant value to
the Company as a tool to reduce cost, and as a intellectual property it can sell
or license to others. In addition, the Company has purchased an online medical
office billing and collection program, which is currently in beta testing.
10
THE QUANTUM GROUP, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO CONDENSED FINANCIAL STATEMENTS - (UNAUDITED)
JANUARY 31, 2005
NOTE 5: ACQUISITION OF QUANTUM MEDICAL TECHNOLOGIES, INC. AND RENAISSANCE HEALTH
SYSTEMS, INC. (continued)
Renaissance Health Systems, Inc. was incorporated in December of 2002, and is a
developmental stage company, with no significant material assets or liabilities
and no revenues, which was formed to create a community health system (CHS) that
will coordinate care to managed care patients by affiliating with providers,
physicians and hospitals. The Company has secured a letter of intent with a
Florida licensed health maintenance organization to build a CHS in three
counties in central Florida. The Company's management has extensive experience
in developing CHS and with recent additions to the staff seeks to complete the
CHS by end of 2nd quarter of 2005.
NOTE 6: LOSS PER SHARE
Basic loss per share is computed by dividing loss available to common
shareholders by the weighted average number of common shares for the period. The
computation of diluted loss per share is similar to basic loss per share, except
that the denominator is increased to include the number of additional common
shares that would have been outstanding if the potentially dilutive common
shares, such as options, had been issued. Diluted loss per share is not
presented as the effects would be anti-dilutive.
NOTE 7: INCENTIVE EQUITY AND STOCK OPTION PLAN
In October 2003 the Company adopted a stock option plan. The purpose of the
stock option plan was to increase the employees and non-employee director's
proprietary interest in Quantum and to align more closely their interests with
the interests of the shareholders of Quantum, as well as to enable Quantum to
attract and retain the services of experienced and highly qualified employees
and non-employees directors.
Options granted under this plan may either be options qualifying as incentive
stock options under Section 422 of the Internal Revenue Code of 1986, as
amended, or options that do not so qualify. Any incentive option must provide
for an exercise price of not less than 100% of the fair market value of the
underlying shares on the date of such grant, but the exercise price of any
incentive option granted to an eligible employee owning more than 10% of the our
common stock must be at least 110% of such fair market value as determined on
the date of the grant.
The term of each option and the manner in which it may be exercised is
determined by the board of directors, provided that no option may be exercisable
more that 10 years after the date of its grant and, in the case of an incentive
option granted to an eligible employee owning more that 10% of the our common
stock, no more than five years after the date of the grant. The board of
directors shall determine the exercise price of non-qualified options.
The Company has reserved 5,000,000 shares of common stock under the plan. The
board of directors or a committee of the board of directors will administer the
plan including, without limitation, the selection of the persons who will be
granted plan options under the plan, the type of plan options to be granted, the
number of shares subject to each plan options and the plan option price.
The per share exercise price of shares granted under the plan may be adjusted in
the event of certain changes in the total purchase price payable upon the
exercise in full of options granted under the plan. Officers, directors and key
employees of and consultants to Quantum will be eligible to receive
non-qualified options under the plan. Only officers, directors and employees of
Quantum who are employed by Quantum or by any subsidiary thereof are eligible to
receive incentive options.
11
THE QUANTUM GROUP, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO CONDENSED FINANCIAL STATEMENTS - (UNAUDITED)
JANUARY 31, 2005
NOTE 7: INCENTIVE EQUITY AND STOCK OPTION PLAN (continued)
The Company has elected to account for the stock options under the Accounting
Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees," and
related interpretations. The Company accounts for stock options granted to
consultants under Financial Accounting Standards Board Statement No. 123,
"Accounting for Stock-Based Compensation."
Under the plan, the Company granted 1,808,000 options, at a weighted average
exercise price of $0.50 per share and 35,750 shares to employees and directors
during the three month period ended January 31, 2005. No options were granted
during the three month period ended January 31, 2004.
A summary of options during the three months ended January 31, 2005 and 2004 is
shown below:
2005 2004
------------------------------------------- ---------------------------------------
Options Options
-------------------------- ----------------------
Weighted Weighted
Incentive Stock Number of Average Common Stock Number of Average
Grants Shares Exercise Price Grants Shares Price
-------------------------------------------- ------------------------------------
Outstanding at beginning of the period 82,000 361,000 -- -- $ --
Granted 99,750 1,808,000 $ 0.50 -- -- $ --
Exercised -- -- $ -- -- -- $ --
Forfeited -- -- $ -- -- -- $ --
--------------------------- --------------------------
Outstanding at January 31 181,750 2,169,000 $ 0.68 -- -- $ --
--------------------------- --------------------------
Exercisable at January 31 187,836 --
Available for issuance at January 31
under the plan 2,649,250 5,000,000
------------- ------------
NOTE 8: OTHER COMMON STOCK TRANSACTIONS
Deferred Compensation
The Company, from time to time, grants shares of common stock to employees,
directors and advisors in lieu of or as partial compensation for services
performed for the Company. These shares vests over two and three year periods.
The value of the stock was determined by the closing market price at the date of
grant. The Company recognized $34,269 and $35,737 in compensation expense
related to these stock grants for the three month periods ended January 31, 2005
and 2004.
The Company recorded $26,512 and $-0- of unearned compensation during the three
month periods ended January 31, 2005 and 2004, respectively, and recorded the
unvested shares as Deferred Compensation - Allocated Shares in the equity
section of the balance sheet
12
THE QUANTUM GROUP, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO CONDENSED FINANCIAL STATEMENTS - (UNAUDITED)
JANUARY 31, 2005
NOTE 8: OTHER COMMON STOCK TRANSACTIONS (continued)
Equity Financing
In June 2004, the Company entered into an agreement with two companies to raise
a minimum of $500,000 to a maximum of $1,000,000. The terms include the share
price to be a 75% discount on the closing sale price. The placement companies
will receive a combined placement fee of 13% of the gross proceeds received from
issuance of shares, a 5% common stock commission and common stock warrants at an
exercise price of $0.275 per share. As of January 31, 2005, the Company received
$381,300 and issued 1,385,289 shares. The Company paid $49,569 in cash and
issued 69,223 shares and 199,170 warrants as commissions.
In December 2005, the Company entered into an agreement with a placement company
to raise capital. The placement company will receive 13% cash commission on the
gross proceeds received from the issuance of the shares and a 5% stock
commission and 5% stock warrants exercisable at the price of stock sold. As of
January 31, 2005, the Company received $200,000 and issued 620,370 shares. The
Company paid $26,000 in cash and issued 31,018 shares as commissions.
Reverse Stock Split
In January 2004, the shareholders of the Company approved the merger of the
Company into The Quantum Group, Inc. for the purpose of reincorporation in the
State of Nevada. In conjunction with the reincorporation, the shareholders
approved a 1 for 10 reverse stock split of its common stock. An amended and
restated Articles of Incorporation have been filed to change the name of the
Company to The Quantum Group, Inc. ("TQGI") and to set the authorized shares of
common stock to 170,000,000 at a par value of $.001 per share and authorized
preferred stock to 30,000,000 at a par value of $.001 per share. All share and
per share amounts have been retroactively restated in the accompanying financial
statements and notes for all periods presented.
NOTE 9: RELATED PARTY TRANSACTIONS
On November 1, 2002, the Company entered into an agreement with a shareholder to
purchase certain intellectual property integral to the Company's business. In
exchange, the company issued a three (3) year installment note for $179,080 with
an interest rate of eighteen percent (18%) per annum. The price of the sale was
equal to the cost the shareholder incurred to develop the property purchased.
The note is payable monthly starting January 2003. The Company is in technical
default as no payments have been made on the note. The Company is accruing
interest, at 18% per annum, monthly on the unpaid principal balance and has
classified the note as current as per the agreement. The interest accrued at
January 31, 2005 is $72,663.
On November 2, 2002 the Company signed a demand note, with an interest rate of
eighteen percent (18%) per annum, for the expenses a shareholder paid on behalf
of the Company subsequent to the sale of the intellectual property. The Company
repaid the note during the quarter ended January 31, 2005. The note payable
balance and accrued interest as of January 31, 2005 are $-0- and $5,502
respectively.
13
THE QUANTUM GROUP, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO CONDENSED FINANCIAL STATEMENTS - (UNAUDITED)
JANUARY 31, 2005
NOTE 10: ACQUISITION OF SOFTWARE
On December 16, 2004, Quantum Medical Technologies, Inc. entered into an
agreement to purchase an application systems provider software from a Florida
Limited Liability Corporation for $80,000. The software was in developmental
stage and has received HIPPA certification. The purchase price is to be paid
over a period of 120 days from the date of closing. Upon review and testing by
an independent software development company, management has determined that
certain representations by the seller were not met and therefore the Company has
not made the second scheduled payment due 60 days from closing. The Company is
seeking to renegotiate or rescind the purchase with the seller
NOTE 11: SUBSEQUENT EVENTS
On February 15, 2005, the Company received $100,000 for the purchase of common
stock at a price of $0.40 per share.
14
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
General
The discussion and analysis set forth below should be read in conjunction with
our Financial Statements and the related notes thereto appearing elsewhere in
this quarterly report. The information presented for the three months ended
January 31 2005 and 2004, was derived from unaudited financial statements,
which, in our opinion, reflect all adjustments (consisting only of normal
recurring adjustments) necessary for a fair presentation.
Forward Looking Statements
This Report on Form 10-QSB contains certain forward-looking statements. When
used in this report, press releases and elsewhere by the management of the
Company from time to time, the words "believes", "anticipates", and "expects"
and similar expressions are intended to identify forward-looking statements that
involve certain risks and uncertainties. Additionally, certain statements
contained in this discussion may be deemed forward-looking statements that
involve a number of risks and uncertainties. Among the factors that could cause
actual results to differ materially are the following: the ability of the
Company to meet its working capital and liquidity needs, economic trends for
consumer advertisers, the availability of long-term credit, unanticipated
changes in the U.S. and international economies, business conditions and growth
in e-commerce and the timely development and acceptance of new products, the
impact of competitive products and pricing, and other risks detailed from time
to time in the Company's SEC reports. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
hereof. The Company undertakes no obligation to publicly release the results of
any events or circumstances after the date hereof or to reflect the occurrence
of unanticipated events.
Going Concern
The Company is a development stage company that over the last three years has
expensed material sums in creating procedures, manuals and systems to assist the
medical community in the implementation of medical regulations. Though the
Company has materially finished developing its training programs, additional
updates and deployment will be required.
As shown in the accompanying condensed financial statements, the Company has
incurred recurring losses and negative cash flows from its development and
organization activities and has negative working capital and shareholders'
deficit. Under normal conditions, these conditions raise substantial doubt about
the Company's ability to continue as a going concern.
There can be no assurance that the Company will be able to successfully
implement its plans to generate additional investor interest and raise
additional capital, or if such plans are successfully implemented, that the
Company will achieve its goals.
Furthermore, if the Company is unable to raise additional funds, it may be
required to modify its growth and developmental plans, and even be forced to
severely limit development operations completely.
The accompanying condensed financial statements have been prepared assuming that
the Company will continue as a going concern and do not include any adjustments
to reflect the possible future effects of the recoverability and classification
of assets or the amounts and classification of liabilities that might result
from the outcome of this uncertainty. See "Liquidity and Capital Resources,"
below.
15
Results of Operations
Three months ended January 31, 2005 and 2004
The expenses for the quarter ended January 31, 2005 were $421,904 compared to
$155,534 for the quarter January 31, 2004. The increase of $266,370 was
primarily due to an increase in personnel, salaries, consulting fees and related
costs and the amortization of deferred compensation of $202,703.
Liquidity and Capital Resources
At January 31, 2005, the Company had working capital deficit of $1,177,552 as
compared to a working capital deficit of $588,404 at January 31, 2004.
Cash inflow from financing activities was $206,450 for the three months ended
January 31, 2005, compared $14,300 for the three months ended January 31, 2004.
The increase was primarily due to the sale of common stock to outside investors
as detailed below. The Company will need to secure additional financing during
the next 12 months.
The Company executed an agreement with an investment group to raise up to
$1,000,000 from foreign investors. These shares will be restricted from sale in
the United States for a minimum of one year. The Company paid commissions and
expenses of 13%, plus legal and support cost relating to this private overseas
offering. Additionally, the Company issued 5% stock commission and issued
199,170 warrants to purchase common stock at a price of $0.275 per share which
expires January 4, 2010. The Company realized net proceeds from the sale of
common stock of $331,731 through January 31, 2005.
During the quarter ended January 31, 2005, the Company entered into an agreement
with a placement firm to raise additional working capital. The terms include a
13% cash commission and a 5% stock commission. The Company has realized net
proceeds from the sale of common stock of $174,000.
The Company's development plan is to identify, negotiate with and acquire
business and services that will allow the Company to provide comprehensive
consulting services, technological, strategic intelligence and systems that will
allow the small to medium size medical organization to provide better care,
better medical outcomes and earn more profit. The Company expect to acquire the
candidate businesses after extensive due diligence, and then to acquire the
business enterprise including cash flow by issuing stock, notes and cash. The
Company expects to secure financing for the acquisition by selling common and/or
preferred shares, issuing debt or notes and by leveraging the potential
acquisition. There is no assurance that the Company will be able to execute on
its plans and clearly, additional financing will be needed to develop and
implement its business plan.
New Accounting Pronouncements
In December 2004, the FASB issued SFAS No. 153 "Exchanges of Non-monetary
Assets-an amendment of APB Opinion No. 29". This Statement amended APB Opinion
No. 29 to eliminate the exception for non-monetary exchanges of similar
productive assets and replaces it with a general exception for exchanges of
non-monetary assets that do not have commercial substance. A non-monetary
exchange has commercial substance if the future cash flows of the entity are
expected to change significantly as a result of the exchange. The Company is
currently evaluating the impact of this new standard, but believes that it will
not have a material impact upon the Company's financial position, results of
operations or cash flows.
16
ITEM 3. CONTROLS AND PROCEDURES
Our Management and resources are limited, as of January 31, 2005 we had only
five full time employees, of which, three were also officers and directors of
the Company. These positions are President/CEO, CFO and Vice President of
Administration, collectively these officers have conducted an evaluation of the
effectiveness of our disclosure controls and procedures (as defined in Rule
13a-15(e) and 15d-15(e) promulgated under the Securities and Exchange Act of
1934, as amended) as of the end of the fiscal quarter covered by this report.
Based upon that evaluation and both our limited developmental history as well as
the size of our organization, our management has concluded that we have adequate
disclosure controls. However we must improve procedures for effective and timely
gathering, analyzing and disclosing the information we are required to disclose
in our reports filed under the Securities Exchange Act of 1934, as amended.
Management expects to add additional controls and personnel in the near future
as capital becomes available. There have been no significant changes made in our
internal controls or in other factors that could significantly affect our
internal controls during the fiscal quarter covered by this report.
17
PART II
OTHER INFORMATION
Item 1. Legal Proceedings
The Company is not a party to any litigation.
Item 2. Changes in Securities
The Company executed an agreement with an investment group to raise up to
$1,000,000 from foreign investors. These shares will be restricted from sale in
the United States for a minimum of one year. The Company paid commissions and
expenses of 13%, plus legal and support cost relating to this private overseas
offering. Additionally, the Company issued 5% stock commission and issued
199,170 warrants to purchase common stock at a price of $0.275 per share which
expires January 4, 2010. The Company realized net proceeds from the sale of
common stock of $331,731 through January 31, 2005.
During the quarter ended January 31, 2005, the Company entered into an agreement
with a placement firm to raise additional working capital. The terms include a
13% cash commission and a 5% stock commission. The Company has realized net
proceeds from the sale of common stock of $174,000.
Item 3. Defaults Upon Senior Securities
As of June 30, 2003, the Company is in default of a $ 179,080, plus accrued
interest of $72,663 obligation to the Company's President and largest
shareholder. He has not declared the note in default as of this time.
Item 4. Submission of Matters to a Vote of Security-Holders
None
Item 5. Other Information
None
Item 6. Exhibits and Reports on Form 8-K.
None
18
Exhibits: Copies of the following documents are included or furnished as
exhibits to this report pursuant to Item 601 of Regulation S-B.
Exhibit SEC Ref. Title of Document
No. No.
-------- -------- --------------------------------------------
31.1 31 Certification of the Chief Executive Officer
and Chief Financial Officer pursuant to
Section 302 of the Sarbanes-Oxley Act of
2002
32.1 32 Certifications of the Chief Executive
Officer and Chief Financial Officer pursuant
to Section 906 of the Sarbanes-Oxley Act of
2002
19
SIGNATURE
In accordance with the requirements of the Securities Exchange Act of 1934, the
Registrant has caused this report to be signed on its behalf by the undersigned,
duly authorized.
THE QUANTUM GROUP, INC.
Date: March 16, 2005
BY: s/ Noel J. Guillama
-------------------
Noel J. Guillama, President
20